Medication info

Ibandrazhu (Ibandronate Sodium Hydrate)

Prescription medicationInjectionsIntravenous injectionExpired
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
An injection solution that is colorless and transparent, contained in a colorless, transparent glass pre-filled syringe with a single-use needle attached.
Packaging
3 milliliters/pre-filled syringe, 1 pre-filled syringe/box
Approval status
Expired

MFDS item code 201903781 · Notified 2019.06.10

This product's status changed to Expired on 2024.06.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L(2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Because clinical experience is insufficient in patients whose serum creatinine is > 200 µmol/L(2.3mg/dL) or whose creatinine clearance is < 30ml/min, administration of this medicine is not recommended. Elderly patients No dose adjustment is required.
Child administration
Efficacy and safety in children aged 18 years or younger have not been studied.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

Postmenopausal osteoporosis is a condition in which bones become weak, increasing the risk of fractures. This medication helps to increase bone density and prevent fractures caused by osteoporosis. It is primarily used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L(2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Because clinical experience is insufficient in patients whose serum creatinine is > 200 µmol/L(2.3mg/dL) or whose creatinine clearance is < 30ml/min, administration of this medicine is not recommended. Elderly patients No dose adjustment is required.

Child administration

Efficacy and safety in children aged 18 years or younger have not been studied.

Precautions

This medication must be administered intravenously, and care should be taken as injection into an artery or around a vein can cause tissue damage. It should not be used in patients with allergies to this drug or its components, or in patients with untreated hypocalcemia. This drug is used for the treatment of osteoporosis and has shown a safety profile similar to placebo in clinical trials; however, various adverse reactions such as gastrointestinal disturbances, myalgia, arthralgia, headache, and rash may occur in some patients. Temporary influenza-like symptoms (joint pain, muscle pain, fever, chills, etc.) may occur with intravenous administration but are mostly mild and resolve without treatment. Serious side effects such as osteonecrosis of the jaw, external auditory canal osteonecrosis, severe allergic reactions, skin abnormalities, and atypical femoral fractures have been reported rarely; therefore, if any abnormal symptoms occur, you should consult a doctor immediately. This drug may temporarily lower serum calcium levels, so hypocalcemia must be treated before administration, and it is important to consume adequate calcium and vitamin D. Patients with poor kidney function or those taking medications that may affect the kidneys need regular monitoring. Patients requiring dental treatment should undergo an oral examination before administration and avoid excessive dental procedures during treatment. Safety for pregnant or breastfeeding women has not been established, so it is recommended not to use it. No dose adjustment is needed for the elderly, but safety and efficacy have not been established in children under 18. In cases of overdose, careful monitoring is required as it may affect kidney and liver function, and appropriate treatment should be administered if electrolyte abnormalities such as hypocalcemia occur. This drug should not be mixed with calcium-containing solutions or other intravenous medications, and used needles and syringes should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral and intertrochanteric femur fracture, dizziness, optic atrophy, lower motor neuron disease, tremor, gastrointestinal disease of unspecified origin, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin exfoliation, sensory loss, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent exposure to air or moisture, preferably at a temperature between 1 degree and 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

An injection solution that is colorless and transparent, contained in a colorless, transparent glass pre-filled syringe with a single-use needle attached.

Package unit

3 milliliters/pre-filled syringe, 1 pre-filled syringe/box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.